← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Prenetics Global Limited (PRE) 10-Year Financial Performance & Capital Metrics

PRE • • Industrial / General
HealthcareDiagnostics & ResearchMolecular Diagnostics & Genetic TestingHereditary & Pharmacogenomic Testing
AboutPrenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.Show more
  • Revenue $31M +40.8%
  • EBITDA -$42M +4.3%
  • Net Income -$46M +26.2%
  • EPS (Diluted) -3.64 +34.8%
  • Gross Margin 50.29% +23.8%
  • EBITDA Margin -137.86% +32.0%
  • Operating Margin -157.23% +34.1%
  • Net Margin -151.22% +47.6%
  • ROE -24.27% +12.2%
  • ROIC -24.76% +14.1%
  • Debt/Equity 0.03 +198.8%
  • Interest Coverage -237.16 +45.3%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Momentum leader: RS Rating 93 (top 7%)
  • ✓Strong 5Y sales CAGR of 27.1%
  • ✓Trading at only 1.1x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 13.0% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y27.1%
3Y34.69%
TTM136.59%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-0.01%

EPS CAGR

10Y-
5Y-
3Y-
TTM10.21%

ROCE

10Y Avg-49.87%
5Y Avg-36.44%
3Y Avg-28.33%
Latest-24.58%

Peer Comparison

Hereditary & Pharmacogenomic Testing
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
PREPrenetics Global Limited226.73M14.87-4.0940.83%-93.53%-33.01%0.03
MYGNMyriad Genetics, Inc.563.01M6.04-4.2811.21%-47.45%-101.83%0.20

Profit & Loss

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+9.23M65.18M12.53M13.16M21.74M30.62M
Revenue Growth %-6.06%-0.81%0.05%0.65%0.41%
Cost of Goods Sold+6.52M38.83M8.93M9.55M12.91M15.22M
COGS % of Revenue0.71%0.6%0.71%0.73%0.59%0.5%
Gross Profit+2.72M26.34M3.6M3.62M8.83M15.4M
Gross Margin %0.29%0.4%0.29%0.27%0.41%0.5%
Gross Profit Growth %-8.7%-0.86%0%1.44%0.74%
Operating Expenses+23.52M27.34M60.26M69.64M60.74M63.54M
OpEx % of Revenue2.55%0.42%4.81%5.29%2.79%2.08%
Selling, General & Admin17.96M23.11M53.67M64.08M49.68M55.37M
SG&A % of Revenue1.94%0.35%4.28%4.87%2.28%1.81%
Research & Development2.99M2.78M6.39M5.99M11.66M10.92M
R&D % of Revenue0.32%0.04%0.51%0.45%0.54%0.36%
Other Operating Expenses2.57M1.45M202.18K-430K-606.84K-2.75M
Operating Income+-20.8M-995.13K-56.66M-66.02M-51.91M-48.14M
Operating Margin %-2.25%-0.02%-4.52%-5.02%-2.39%-1.57%
Operating Income Growth %-0.95%-55.94%-0.17%0.21%0.07%
EBITDA+-18.57M1.43M-49.32M-58.48M-44.11M-42.22M
EBITDA Margin %-2.01%0.02%-3.93%-4.44%-2.03%-1.38%
EBITDA Growth %-1.08%-35.46%-0.19%0.25%0.04%
D&A (Non-Cash Add-back)2.23M2.43M7.35M7.54M7.79M5.93M
EBIT-20.8M-3.84M-216.51M-225.58M-55.69M-57.5M
Net Interest Income+-53.88K-51.52K-42.03K230K3.8M1.84M
Interest Income15.51K8.04K201472K3.92M2.04M
Interest Expense69.39K59.57K42.23K242K119.66K203K
Other Income/Expense-69.39K-2.91M-159.89M-159.8M-4.76M-9.56M
Pretax Income+-20.87M-3.9M-216.55M-225.82M-56.67M-57.7M
Pretax Margin %-2.26%-0.06%-17.28%-17.15%-2.61%-1.88%
Income Tax+-677.47K-1.94M2.57M-245K-269.36K-7.87M
Effective Tax Rate %0.96%0.5%0.8%0.84%1.11%0.8%
Net Income+-20.14M-1.94M-174.01M-190.45M-62.72M-46.3M
Net Margin %-2.18%-0.03%-13.88%-14.47%-2.88%-1.51%
Net Income Growth %-0.9%-88.71%-0.09%0.67%0.26%
Net Income (Continuing)-20.2M-1.96M-219.12M-225.58M-56.4M-49.83M
Discontinued Operations0045.11M35.12M-8.38M22K
Minority Interest-53.21K-77.41K-84.97K6.4M3.8M957K
EPS (Diluted)+-2.73-0.26-47.04-37.57-5.58-3.64
EPS Growth %-0.9%-179.92%0.2%0.85%0.35%
EPS (Basic)-2.73-0.26-47.04-37.57-5.58-3.64
Diluted Shares Outstanding7.4M7.4M3.7M5.07M11.25M12.71M
Basic Shares Outstanding7.4M7.4M3.7M5.07M11.25M12.71M
Dividend Payout Ratio------

Balance Sheet

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+15.63M43.96M106.89M241.81M93.66M86.15M
Cash & Short-Term Investments11.82M14.8M45.19M184.12M72.74M62.81M
Cash Only11.52M14.49M35.29M146.66M45.71M52.25M
Short-Term Investments294.06K314.71K9.91M37.46M27.03M10.56M
Accounts Receivable2.89M23.1M47.05M42.5M5.29M5.61M
Days Sales Outstanding114.34129.341.37K1.18K88.8766.81
Inventory547.85K4.5M6.83M4.53M3.13M6.57M
Days Inventory Outstanding30.6842.27279.13173.3688.39157.45
Other Current Assets374.36K979.6K7.31M4.58M8.31M3.55M
Total Non-Current Assets+14.06M34.93M41.61M70.32M160.51M127.43M
Property, Plant & Equipment2.11M4.69M13.04M13.1M5.78M7.81M
Fixed Asset Turnover4.37x13.89x0.96x1.00x3.76x3.92x
Goodwill3.85M3.99M3.98M33.8M29.17M37.36M
Intangible Assets6.27M23.96M23.83M14.79M13.43M11.57M
Long-Term Investments1.66M00788.47K107.84M69.33M
Other Non-Current Assets161K2.28M693.55K7.6M4.27M1.35M
Total Assets+29.69M78.88M148.51M312.13M254.17M213.57M
Asset Turnover0.31x0.83x0.08x0.04x0.09x0.14x
Asset Growth %-1.66%0.88%1.1%-0.19%-0.16%
Total Current Liabilities+11.9M47.07M58.74M57.2M39.48M36.55M
Accounts Payable2.76M13.44M9.98M7.29M1.67M3.67M
Days Payables Outstanding154.61126.29407.9278.7847.2387.96
Short-Term Debt015.47M1.67M000
Deferred Revenue (Current)001000K1000K1000K1000K
Other Current Liabilities7.79M10.92M22.64M17.47M15.49M15.07M
Current Ratio1.31x0.93x1.82x4.23x2.37x2.36x
Quick Ratio1.27x0.84x1.70x4.15x2.29x2.18x
Cash Conversion Cycle-9.645.321.24K1.07K130.03136.31
Total Non-Current Liabilities+930.56K804.57K490.66M11.47M4.53M5.68M
Long-Term Debt124.32K0486.4M000
Capital Lease Obligations775.23K804.57K3.6M3.76M867K3.01M
Deferred Tax Liabilities00659.5K3.19M2.62M2.17M
Other Non-Current Liabilities31.01K004.52M1.05M499K
Total Liabilities12.83M47.88M549.4M68.67M44.01M42.23M
Total Debt+1.46M17.14M491.67M6.65M2.37M5.77M
Net Debt-10.07M2.65M456.38M-140.01M-43.34M-46.48M
Debt / Equity0.09x0.55x-0.03x0.01x0.03x
Debt / EBITDA-11.98x----
Net Debt / EBITDA-1.86x----
Interest Coverage-299.80x-16.71x-1341.78x-272.82x-433.78x-237.16x
Total Equity+16.85M31.01M-400.89M243.46M210.16M171.35M
Equity Growth %-0.84%-13.93%1.61%-0.14%-0.18%
Book Value per Share2.284.19-108.3748.0318.6913.49
Total Shareholders' Equity16.91M31.08M-400.81M237.06M206.36M170.39M
Common Stock45.69M15.35M1.49K13.7K18K19K
Retained Earnings-41.64M-43.58M0-408.04M-470.77M-517.07M
Treasury Stock000-661.52K-62K-639K
Accumulated OCI12.86M21.42M-400.81M-185.69M-176.03M-169.25M
Minority Interest-53.21K-77.41K-84.97K6.4M3.8M957K

Cash Flow

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-1.88M-2.88M13.42M14.51M-13.76M-28.87M
Operating CF Margin %-0.2%-0.04%1.07%1.1%-0.63%-0.94%
Operating CF Growth %--0.53%5.66%0.08%-1.95%-1.1%
Net Income-20.2M-1.96M-174.02M-190.45M-64.78M-49.81M
Depreciation & Amortization2.23M2.43M7.35M7.54M7.79M5.93M
Stock-Based Compensation3.91M1.62M22.49M31.58M10.59M11.98M
Deferred Taxes-677.47K-1.94M3.73M7.15M-385.84K-7.87M
Other Non-Cash Items2.64M4.77M160.45M192.46M8.8M8.93M
Working Capital Changes10.21M-7.79M-6.59M-33.76M24.21M1.97M
Change in Receivables1.83M-20.09M-24.06M6.97M37.63M-428K
Change in Inventory415.69K-3.75M-2.33M1.26M-1.73M1.32M
Change in Payables1.71M9.71M-3.46M-2.63M-5.62M-4.68M
Cash from Investing+-4.6M-5.97M-22.02M-46.14M-82.95M38.54M
Capital Expenditures-373.86K-3.06M-8.55M-6.34M-345.29K-1.01M
CapEx % of Revenue0.04%0.05%0.68%0.48%0.02%0.03%
Acquisitions------
Investments------
Other Investing12.43K14.75K-3.47M531.99K-76.52M2.02M
Cash from Financing+-569.14K11.84M29.32M143.32M-4.7M-3.34M
Debt Issued (Net)------
Equity Issued (Net)------
Dividends Paid000000
Share Repurchases------
Other Financing-65.55K12.45M4.65M145.86M-241.5K-203K
Net Change in Cash------
Free Cash Flow+-2.26M-5.94M2M8.17M-14.68M-29.94M
FCF Margin %-0.24%-0.09%0.16%0.62%-0.68%-0.98%
FCF Growth %--1.63%1.34%3.08%-2.8%-1.04%
FCF per Share-0.31-0.800.541.61-1.31-2.36
FCF Conversion (FCF/Net Income)0.09x1.48x-0.08x-0.08x0.22x0.62x
Interest Paid000000
Taxes Paid000000

Key Ratios

Metric201920202021202220232024
Return on Equity (ROE)-119.52%-8.11%--78.23%-27.65%-24.27%
Return on Invested Capital (ROIC)-229.9%-3.69%-95.34%-62.31%-28.81%-24.76%
Gross Margin29.41%40.42%28.75%27.48%40.61%50.29%
Net Margin-218.15%-2.98%-1388.44%-1446.78%-288.48%-151.22%
Debt / Equity0.09x0.55x-0.03x0.01x0.03x
Interest Coverage-299.80x-16.71x-1341.78x-272.82x-433.78x-237.16x
FCF Conversion0.09x1.48x-0.08x-0.08x0.22x0.62x
Revenue Growth-605.93%-80.77%5.04%65.17%40.83%

Revenue by Geography

202220232024
HONG KONG210.93M12.92M14.27M
HONG KONG Growth--93.88%10.45%
TAIWAN-9.33M7.09M
TAIWAN Growth---23.95%
UNITED STATES--5.51M
UNITED STATES Growth---
Rest Of The World-1.18M972K
Rest Of The World Growth---17.92%

Frequently Asked Questions

Growth & Financials

Prenetics Global Limited (PRE) reported $53.3M in revenue for fiscal year 2024. This represents a 477% increase from $9.2M in 2019.

Prenetics Global Limited (PRE) grew revenue by 40.8% over the past year. This is strong growth.

Prenetics Global Limited (PRE) reported a net loss of $49.8M for fiscal year 2024.

Dividend & Returns

Prenetics Global Limited (PRE) has a return on equity (ROE) of -24.3%. Negative ROE indicates the company is unprofitable.

Prenetics Global Limited (PRE) had negative free cash flow of $29.9M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.